Products

Tukavo 150mg Tablet (Tucatinib): Advanced HER2-Specific Tyrosine Kinase Inhibitor Tukavo 150 mg Tablet is a highly specialized oral antineoplastic agent containing the active ingredient Tucatinib. Developed as a next-generation Tyrosine Kinase Inhibitor (TKI), Tukavo is specifically engineered to target the Human Epidermal Growth Factor Receptor 2 (HER2). It has become a cornerstone in the treatment of advanced HER2-positive breast cancers, offering new hope for patients, including those with difficult-to-treat brain metastases. Therapeutic Indications and Clinical Usage Tukavo 150 mg is utilized globally in advanced oncology settings for: HER2-Positive Metastatic Breast Cancer: Indicated for adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It is typically used in a triple-combination regimen with Trastuzumab and Capecitabine. Brain Metastases Management: Tukavo is uniquely effective because it can cross the blood-brain barrier. It is indicated for patients with or without brain metastases who have received one or more prior anti-HER2-based regimens. RAS Wild-Type Colorectal Cancer: In specific regulatory jurisdictions, it is used in combination with Trastuzumab for adult patients with HER2-positive metastatic colorectal cancer that has progressed after standard chemotherapy. Mechanism of Action: How Tukavo 150mg Works Tukavo works through a highly selective process of intracellular signaling blockade: Selective HER2 Inhibition: Unlike older TKIs that target multiple receptors, Tucatinib is highly selective for the HER2 protein. This selectivity helps minimize “off-target“ side effects like severe skin rashes or diarrhea associated with EGFR inhibition. Phosphorylation Blockade: By binding to the internal domain of the HER2 receptor, it prevents the phosphorylation process. This effectively shuts down the downstream signaling pathways (like MAPK and PI3K/Akt) that tell the cancer cell to multiply. Synergistic Effect: When used with Trastuzumab (which binds to the outside of the cell), Tukavo provides a “dual blockade,“ attacking the HER2 signaling from both the inside and the outside of the cancer cell. Blood-Brain Barrier Penetration: Its small molecular structure allows it to reach the central nervous system, making it a vital tool for treating cancer that has spread to the brain. Dosage and Administration Guidelines Standard Dosage: The recommended dose is 300 mg (two 150 mg tablets) taken orally twice daily. Administration: Tablets must be swallowed whole. Do not chew, crush, or break the tablets. Consistency: Can be taken with or without food. It is best to take doses approximately 12 hours apart at the same time each day. Missed Dose: If a dose is missed or vomited, the patient should skip that dose and take the next one at the regularly scheduled time. Safety Profile and Professional Monitoring Treatment with Tukavo 150 mg requires close medical supervision: 1. Hepatotoxicity Monitoring Tukavo can affect liver function. Regular liver function tests (ALT, AST, and Bilirubin) are mandatory before starting treatment and every three weeks during therapy. 2. Gastrointestinal Support Diarrhea is a common side effect. Patients should be prepared with anti-diarrheal medications (like loperamide) and maintain high fluid intake. 3. General Side Effects Other commonly reported symptoms include fatigue, nausea, vomiting, stomatitis (mouth sores), and “hand-foot syndrome“ (redness or swelling of the palms and soles). 4. Embryo-Fetal Toxicity Tucatinib can cause fetal harm. Effective contraception is required for females of reproductive potential and their male partners during treatment and for at least one week after the final dose. Storage and Global Handling Temperature: Store at room temperature, 20°C to 25°C (68°F to 77°F). Original Packaging: Keep the tablets in their original container with the desiccant to protect them from moisture. Handling: Dispose of any unused Tukavo 3 months after opening the bottle. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Olpaza 150mg Tablet (Olaparib): Advanced PARP Inhibitor for Targeted Cancer Therapy Olpaza 150mg Tablet is a specialized, targeted anti-cancer medication containing the active ingredient Olaparib. It belongs to a revolutionary class of drugs known as PARP (poly [adenosine diphosphate-ribose] polymerase) inhibitors. Manufactured by Intas Pharmaceuticals Ltd., Olpaza 150mg represents a breakthrough in precision medicine, specifically designed to exploit genetic vulnerabilities in cancer cells to induce “synthetic lethality.“ Therapeutic Indications and Clinical Usage Olpaza 150mg is utilized globally for the management of advanced malignancies, particularly those associated with BRCA1/BRCA2 gene mutations: Ovarian Cancer: Used as maintenance treatment for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients who are in complete or partial response to first-line platinum-based chemotherapy. Breast Cancer: Indicated for the treatment of gBRCA-mutated, HER2-negative metastatic breast cancer in patients previously treated with chemotherapy. Pancreatic Cancer: Employed for the maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on first-line platinum-based chemotherapy. Prostate Cancer: Indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene mutations. Mechanism of Action: How Olpaza 150mg Works Olpaza works by specifically targeting the DNA repair machinery within cancer cells: PARP Inhibition: PARP enzymes are essential for repairing single-strand breaks in DNA. Olpaza binds to and inhibits these enzymes. DNA Damage Accumulation: When PARP is blocked, single-strand DNA breaks transition into double-strand breaks during replication. Synthetic Lethality: In cancer cells with existing DNA repair deficiencies (like BRCA mutations), these double-strand breaks cannot be repaired, leading to genomic instability and programmed cell death (apoptosis). Sparing Healthy Cells: Because normal cells have intact alternative DNA repair pathways, they are significantly less affected by Olpaza than cancerous ones. Dosage and Administration Guidelines Standard Dosage: The typical adult dose is 300 mg (two 150 mg tablets) taken twice daily, totaling 600 mg per day. Administration: Tablets must be swallowed whole with water and should not be chewed, crushed, or dissolved. Flexibility: Can be taken with or without food. It is recommended to take doses approximately 12 hours apart at the same time each day. Dose Adjustments: Oncologists may modify the dosage based on individual patient tolerance, renal function, or the occurrence of specific side effects. Safety Profile and Side Effect Management As a potent targeted therapy, Olpaza 150mg requires professional clinical monitoring: 1. Hematological Monitoring Common side effects include anemia, neutropenia (low white blood cell count), and thrombocytopenia (low platelet count). Regular blood tests (CBC) are required before and during treatment. 2. Gastrointestinal Support Nausea, vomiting, and diarrhea are frequently reported. These are often managed with anti-emetic medications and by maintaining adequate hydration (8–10 glasses of water daily). 3. Respiratory Vigilance While rare, inflammation of the lungs (pneumonitis) can occur. Patients should report any new or worsening shortness of breath or cough immediately. 4. Embryo-Fetal Toxicity Olaparib can cause fetal harm. Effective contraception is mandatory for both female and male patients of reproductive potential during and for several months after the final dose. Storage and Handling Temperature: Store below 30°C in a dry place. Protection: Keep the bottle tightly closed and away from direct sunlight and moisture. Safety: Store out of reach of children and pets. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Lenid 10mg Capsule (Lenalidomide): Precision Immunotherapy for Hematological Malignancies Lenid 10mg Capsule is a high-potency anti-cancer medication featuring the active pharmaceutical ingredient Lenalidomide. Classified as an immunomodulatory imide drug (IMiD), Lenid 10mg is a critical therapeutic agent used globally to treat various forms of blood and bone marrow cancers. Manufactured by Natco Pharma Ltd., a global pioneer in oncology generics, Lenid is recognized for its high efficacy in modulating the immune response to identify and destroy malignant cells while inhibiting tumor growth. Therapeutic Indications and Clinical Usage Lenid 10mg is a primary choice in international oncology protocols for: Multiple Myeloma (MM): Indicated for adult patients with newly diagnosed multiple myeloma, often used in combination with dexamethasone. It is also a gold-standard choice for maintenance therapy following autologous stem cell transplantation (ASCT). Myelodysplastic Syndromes (MDS): Specifically used for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after at least two prior therapies. Follicular Lymphoma (FL): Used in combination with rituximab for previously treated adult patients with follicular or marginal zone lymphoma. Mechanism of Action: How Lenid 10mg Works Lenid exerts its therapeutic effects through a multi-dimensional biological approach: Immune System Augmentation: It enhances the activity of T-cells and Natural Killer (NK) cells, empowering the body's natural defenses to destroy cancer cells more aggressively. Direct Antitumor Activity: It induces cell cycle arrest and triggers apoptosis (programmed cell death) in malignant hematopoietic cells. Anti-Angiogenesis: It blocks the formation of new blood vessels that tumors rely on for oxygen and nutrients, effectively “starving“ the tumor. Cytokine Regulation: It inhibits the production of pro-inflammatory cytokines such as TNF-alpha and IL-6, which are known to fuel the proliferation of myeloma cells. Dosage and Administration Guidelines Dosing Schedule: Usually administered in 28-day cycles. The 10 mg strength is frequently utilized for maintenance therapy or adjusted dosing based on patient tolerance and renal function. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Consistency: Can be taken with or without food, but should be taken at approximately the same time each day to maintain steady therapeutic levels. Clinical Monitoring: Dosage adjustments are strictly managed by oncologists based on renal function and blood cell counts. Safety Profile and Side Effect Management As a potent targeted therapy, Lenid 10mg requires vigilant professional oversight: 1. Hematological Vigilance The most common side effects include neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular Complete Blood Counts (CBC) are mandatory to monitor for infection or bleeding risks. 2. Thromboembolism Prophylaxis There is an increased risk of blood clots (DVT or Pulmonary Embolism). Patients are typically prescribed prophylactic anticoagulants (like aspirin or heparin) concurrently. 3. Embryo-Fetal Toxicity (REMS) Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients of reproductive potential. 4. General Side Effects Commonly reported symptoms include fatigue, diarrhea, muscle cramps, and skin rashes. These are usually managed with supportive care. Storage and Handling Instructions Temperature: Store at room temperature, 20°C to 25°C (68°F to 77°F). Protection: Keep capsules in the original blister packaging to protect from light and moisture. Safety: Caregivers should avoid direct skin contact with the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Lenmid 10mg Capsule (Lenalidomide): Precision Immunotherapy for Hematological Malignancies Lenmid 10mg Capsule is a high-potency anti-cancer medication featuring the active pharmaceutical ingredient Lenalidomide. Classified as an immunomodulatory imide drug (IMiD), Lenmid 10mg is a critical therapeutic agent used globally to treat various forms of blood and bone marrow cancers. Manufactured by Cipla Ltd., a global leader in life-saving pharmaceuticals, it is recognized for its high efficacy in modulating the immune system to identify and destroy malignant cells while inhibiting tumor growth. Therapeutic Indications and Clinical Usage Lenmid 10mg is a primary choice in international oncology protocols for: Multiple Myeloma (MM): Indicated for adult patients with newly diagnosed Multiple Myeloma, often used in combination with dexamethasone. It is also a gold-standard choice for maintenance therapy following autologous stem cell transplantation (ASCT). Myelodysplastic Syndromes (MDS): Specifically used for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after at least two prior therapies. Follicular Lymphoma (FL): Used in combination with rituximab for previously treated adult patients with follicular or marginal zone lymphoma. Mechanism of Action: How Lenmid 10mg Works Lenmid exerts its therapeutic effects through a multi-dimensional biological approach: Immune System Augmentation: It enhances the activity of T-cells and Natural Killer (NK) cells, empowering the body's natural defenses to destroy cancer cells more aggressively. Direct Antitumor Activity: It induces cell cycle arrest and triggers apoptosis (programmed cell death) in malignant hematopoietic cells. Anti-Angiogenesis: It blocks the formation of new blood vessels that tumors rely on for oxygen and nutrients, effectively “starving“ the tumor. Cytokine Regulation: It inhibits the production of pro-inflammatory cytokines such as TNF-alpha and IL-6, which are known to fuel the proliferation of myeloma cells. Dosage and Administration Guidelines Dosing Schedule: Usually administered in 28-day cycles. The 10 mg strength is frequently utilized for maintenance therapy or adjusted dosing based on patient tolerance. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Consistency: Can be taken with or without food, but should be taken at approximately the same time each day to maintain steady therapeutic levels. Clinical Monitoring: Dosage adjustments are strictly managed by oncologists based on renal function and blood cell counts. Safety Profile and Side Effect Management As a potent targeted therapy, Lenmid 10mg requires vigilant professional oversight: 1. Hematological Vigilance The most common side effects include neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular Complete Blood Counts (CBC) are mandatory to monitor for infection or bleeding risks. 2. Thromboembolism Prophylaxis There is an increased risk of blood clots (DVT or Pulmonary Embolism). Patients are typically prescribed prophylactic anticoagulants (like aspirin or heparin) concurrently. 3. Embryo-Fetal Toxicity (REMS) Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients of reproductive potential. 4. General Side Effects Commonly reported symptoms include fatigue, diarrhea, muscle cramps, and skin rashes. These are usually managed with supportive care. Storage and Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Protection: Keep capsules in the original blister packaging to protect from light and moisture. Safety: Caregivers should avoid direct skin contact with the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Lenome 10mg Capsule (Lenalidomide): Advanced Immunomodulatory Therapy for Hematological Malignancies Lenome 10 mg Capsule is a high-potency anti-cancer medication featuring the active pharmaceutical ingredient Lenalidomide. Classified as an immunomodulatory imide drug (IMiD), Lenome 10mg is a critical therapeutic agent used globally to treat various forms of blood and bone marrow cancers. Manufactured by Intas Pharmaceuticals Ltd., it is recognized for its high efficacy in modulating the immune system to identify and destroy malignant cells while inhibiting tumor growth. Therapeutic Indications and Clinical Usage Lenome 10mg is a primary choice in international oncology protocols for: Multiple Myeloma (MM): Indicated for adult patients with newly diagnosed Multiple Myeloma, often used in combination with dexamethasone. It is also a gold-standard choice for maintenance therapy following autologous stem cell transplantation (ASCT). Myelodysplastic Syndromes (MDS): Specifically used for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after at least two prior therapies. Follicular Lymphoma (FL): Used in combination with rituximab for previously treated adult patients with follicular or marginal zone lymphoma. Mechanism of Action: How Lenome 10mg Works Lenome exerts its therapeutic effects through a multi-dimensional biological approach: Immune System Augmentation: It enhances the activity of T-cells and Natural Killer (NK) cells, empowering the body's natural defenses to destroy cancer cells more aggressively. Direct Antitumor Activity: It induces cell cycle arrest and triggers apoptosis (programmed cell death) in malignant hematopoietic cells. Anti-Angiogenesis: It blocks the formation of new blood vessels that tumors rely on for oxygen and nutrients, effectively “starving“ the tumor. Cytokine Regulation: It inhibits the production of pro-inflammatory cytokines such as TNF-alpha and IL-6, which are known to fuel the proliferation of myeloma cells. Dosage and Administration Guidelines Dosing Schedule: Usually administered in 28-day cycles. The 10 mg strength is frequently utilized for maintenance therapy or adjusted dosing based on patient tolerance. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Consistency: Can be taken with or without food, but should be taken at approximately the same time each day to maintain steady therapeutic levels. Clinical Monitoring: Dosage adjustments are strictly managed by oncologists based on renal function and blood cell counts. Safety Profile and Side Effect Management As a potent targeted therapy, Lenome 10mg requires vigilant professional oversight: 1. Hematological Vigilance The most common side effects include neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular Complete Blood Counts (CBC) are mandatory to monitor for infection or bleeding risks. 2. Thromboembolism Prophylaxis There is an increased risk of blood clots (DVT or Pulmonary Embolism). Patients are typically prescribed prophylactic anticoagulants (like aspirin or heparin) concurrently. 3. Embryo-Fetal Toxicity (REMS) Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients of reproductive potential. 4. General Side Effects Commonly reported symptoms include fatigue, diarrhea, muscle cramps, and skin rashes. These are usually managed with supportive care. Storage and Handling Instructions Temperature: Store at room temperature, 20°C to 25°C (68°F to 77°F). Protection: Keep capsules in the original blister packaging to protect from light and moisture. Safety: Caregivers should avoid direct skin contact with the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Lynide 10mg Capsule is a high-potency immunomodulatory drug (IMiD) featuring the active pharmaceutical ingredient Lenalidomide. It is a cornerstone therapy in modern hematology and oncology, specifically designed to treat various plasma cell dyscrasias and complex blood cancers. Manufactured by Hetero Healthcare Ltd., a global leader in life-saving medications, Lynide 10mg offers a targeted approach to inhibiting tumor growth while stimulating the body's natural immune response. Therapeutic Indications and Clinical Usage Lynide 10mg is extensively utilized across global oncology protocols for: Multiple Myeloma (MM): Often used as maintenance therapy following autologous stem cell transplantation (ASCT) or in combination with dexamethasone for patients with newly diagnosed or relapsed MM. Myelodysplastic Syndromes (MDS): Specifically indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after at least two prior therapies. Follicular Lymphoma & Marginal Zone Lymphoma: Employed in combination with rituximab for previously treated patients to achieve better remission rates. The Mechanism: How Lynide 10mg Works Lynide exerts its anti-cancer effects through a sophisticated multi-pathway mechanism: Immune Modulation: It enhances T-cell and Natural Killer (NK) cell-mediated immunity, significantly increasing the body's innate ability to identify and destroy malignant cells. Anti-Angiogenesis: It blocks the secretion of vascular endothelial growth factor (VEGF), effectively preventing the formation of new blood vessels that tumors need to survive. Direct Cytotoxicity: It induces cell cycle arrest and apoptosis (programmed cell death) specifically in hematopoietic tumor cells. Anti-Inflammatory Action: It inhibits the production of pro-inflammatory cytokines such as TNF-alpha and various Interleukins (IL-1, IL-6, and IL-12). Dosage and Administration Guidelines Cycle-Based Dosing: Typically administered in 28-day cycles. The 10 mg strength is frequently used during the maintenance phase or for dose adjustments based on patient tolerance. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Timing: Can be taken with or without food, but should be taken at the same time each day to maintain steady therapeutic levels. Renal Monitoring: Since the drug is primarily excreted by the kidneys, dosage adjustments are strictly managed for patients with impaired renal function. Safety Profile and Side Effect Management Clinical management of Lynide 10 mg requires vigilant professional oversight: 1. Hematological Support The most frequent side effects are neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular blood counts (CBC) are mandatory to monitor for infection or bleeding risks. 2. Thromboembolism Prophylaxis There is a significantly increased risk of blood clots (DVT or Pulmonary Embolism). Patients are often prescribed prophylactic anticoagulants alongside Lynide. 3. Embryo-Fetal Toxicity (REMS) Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients of reproductive potential. 4. General Side Effects Commonly reported symptoms include fatigue, diarrhea, muscle cramps, and skin rashes. These are typically managed with supportive care and symptomatic treatment. Storage and Handling Temperature: Store at room temperature, 20°C to 25°C. Security: Keep in the original blister pack to protect from light and moisture. Safety: Caregivers should avoid direct skin contact with the powder inside the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Relidomide 10mg Capsule is a high-potency immunomodulatory drug (IMiD) featuring the active pharmaceutical ingredient Lenalidomide. It is a cornerstone therapy in modern hematology and oncology, specifically designed to treat various plasma cell dyscrasias and complex blood cancers. Manufactured by Reliance Life Sciences, a leader in biotechnology and biopharmaceuticals, Relidomide 10mg offers a targeted approach to inhibiting tumor growth while stimulating the body's natural immune response. Therapeutic Indications and Clinical Usage Relidomide 10mg is extensively utilized across global oncology protocols for: Multiple Myeloma (MM): Used in combination with dexamethasone for patients with newly diagnosed multiple myeloma or those who have received at least one prior therapy. It is also a primary choice for maintenance therapy following autologous stem cell transplantation (ASCT). Myelodysplastic Syndromes (MDS): Specifically indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after at least two prior therapies, providing a vital line of defense. Follicular Lymphoma & Marginal Zone Lymphoma: Employed in combination with rituximab for previously treated patients to achieve better remission rates and progression-free survival. The Mechanism: How Relidomide 10mg Works Relidomide exerts its anti-cancer effects through a sophisticated multi-pathway mechanism: Immune Modulation: It enhances T-cell and Natural Killer (NK) cell-mediated immunity, significantly increasing the body's innate ability to identify and destroy malignant cells. Anti-Angiogenesis: It blocks the secretion of vascular endothelial growth factor (VEGF), effectively preventing the formation of new blood vessels that tumors need to survive and spread. Direct Cytotoxicity: It induces cell cycle arrest and apoptosis (programmed cell death) specifically in hematopoietic tumor cells. Anti-Inflammatory Action: It inhibits the production of pro-inflammatory cytokines such as TNF-alpha and various Interleukins (IL-1, IL-6, and IL-12). Dosage and Administration Guidelines Cycle-Based Dosing: Typically administered in 28-day cycles. For Multiple Myeloma, the standard dose is adjusted by the oncologist, often starting with higher strengths and moving to 10mg for maintenance or specific cycles. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Timing: Can be taken with or without food, but should be taken at the same time each day to maintain steady therapeutic levels.Renal Monitoring: Since the drug is primarily excreted by the kidneys, dosage adjustments are strictly managed for patients with impaired renal function. Safety Profile and Side Effect Management Clinical management of Relidomide 10 mg requires vigilant professional oversight: 1. Hematological Support The most frequent side effects are neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular blood counts (CBC) are mandatory to monitor for infection or bleeding risks. 2. Thromboembolism Prophylaxis There is a significantly increased risk of blood clots (DVT or Pulmonary Embolism). Patients are almost always prescribed prophylactic anticoagulants (like aspirin or heparin) alongside Relidomide. 3. Embryo-Fetal Toxicity (REMS) Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs is mandatory for all patients of reproductive potential. 4. General Side Effects Commonly reported symptoms include fatigue, diarrhea, muscle cramps, and skin rashes. These are typically managed with supportive care and symptomatic medication. Storage and Handling Temperature: Store at room temperature, 20°C to 25°C. Security: Keep in the original blister pack to protect from light and moisture. Safety: Caregivers should avoid direct skin contact with the powder inside the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Braunamide 10mg Capsule (Lenalidomide): Advanced Immunomodulatory Therapy for Blood Cancers Braunamide 10mg Capsule is a high-potency anti-cancer medication featuring the active pharmaceutical ingredient Lenalidomide. Manufactured by Samarth Life Sciences Pvt. Ltd., Braunamide is a generic equivalent of the internationally recognized immunomodulatory agent Revlimid®. It is primarily used in the treatment and management of complex hematological malignancies, including Multiple Myeloma and Myelodysplastic Syndromes (MDS). As a targeted immunotherapy, Braunamide 10mg offers a sophisticated approach to oncology care by modulating the immune system to recognize and eliminate malignant cells more effectively. Therapeutic Indications and Clinical Usage Braunamide 10mg is a cornerstone in international hematology-oncology protocols for: Multiple Myeloma (MM): Used in combination with Dexamethasone for adult patients with newly diagnosed or relapsed/refractory Multiple Myeloma. It is also used as maintenance therapy following autologous stem cell transplantation. Myelodysplastic Syndromes (MDS): Specifically indicated for patients with transfusion-dependent anemia due to low or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after at least two prior therapies, including one containing Bortezomib. Follicular Lymphoma (FL): Used in combination with Rituximab for previously treated adult patients with follicular or marginal zone lymphoma. Mechanism of Action: How Braunamide 10mg Works The active molecule, Lenalidomide, exerts its anti-cancer effects through a multi-pathway biological attack: Immune System Stimulation: It enhances the function of T-cells and Natural Killer (NK) cells, empowering the body's own immune system to target and destroy cancer cells. Anti-Angiogenesis: It inhibits the growth of new blood vessels within a tumor, effectively “starving“ the cancer cells of the nutrients they need to grow. Direct Antitumor Effect: It triggers apoptosis (programmed cell death) in malignant cells and prevents them from multiplying. Cytokine Regulation: It restricts the production of chemical messengers (pro-inflammatory cytokines) that are responsible for the proliferation of cancer cells in the bone marrow. Dosage and Administration Guidelines Cycle Management: The dosage is determined by a specialist based on the condition being treated. It is often taken once daily on a specific schedule (e.g., Days 1–21 of a 28-day cycle). Method of Intake: Swallow the 10mg capsule whole with a glass of water. Do not break, crush, or chew the capsule. Consistency: Braunamide can be taken with or without food, but should be taken at approximately the same time each day to maintain steady therapeutic levels. Compliance: Do not stop taking the medication or adjust the dose without consulting your hematologist-oncologist. Safety Profile and Professional Monitoring Treatment with Braunamide 10mg requires close medical supervision to manage potential side effects: Hematological Vigilance: Common side effects include neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular Complete Blood Counts (CBC) are required to monitor for infection or bleeding risks. Thromboembolism Risk: There is an increased risk of blood clots in the veins and arteries. Prophylactic anticoagulants are often prescribed concurrently. Embryo-Fetal Toxicity (REMS): Lenalidomide is a known teratogen. It must never be used during pregnancy, and strict contraception protocols (REMS program) are mandatory for both male and female patients. General Effects: Patients may experience fatigue, constipation, diarrhea, or muscle cramps. Consult your doctor if these symptoms persist. Storage and Handling Instructions Temperature: Store at room temperature, 20°C to 25°C (68°F to 77°F). Security: Keep capsules in the original blister pack to protect from light and moisture. Safety: Caregivers should avoid direct skin contact with the powder inside the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383

Bdpoma 4mg Capsule (Pomalidomide): Potent Immunomodulatory Agent for Refractory Multiple Myeloma Bdpoma 4mg Capsule is a high-potency anti-cancer medication featuring the active pharmaceutical ingredient Pomalidomide. It belongs to the third generation of immunomodulatory imide drugs (IMiDs). Developed to address the needs of patients with complex hematological malignancies, Bdpoma 4mg is a critical therapeutic intervention for those who have developed resistance to previous lines of treatment, such as Lenalidomide or Bortezomib. Therapeutic Indications and Clinical Usage Bdpoma 4 mg is utilized across major international oncology protocols for: Relapsed and Refractory Multiple Myeloma (RRMM): Specifically indicated for adult patients who have received at least two prior therapies (including a proteasome inhibitor and an immunomodulatory agent) and have shown disease progression on or within 60 days of the last therapy. Combination Regimens: In clinical practice, Bdpoma is most effective when administered in combination with low-dose Dexamethasone, significantly improving progression-free survival rates. Kaposi Sarcoma (KS): Used for patients with AIDS-related Kaposi Sarcoma that has become resistant to highly active antiretroviral therapy (HAART) or for HIV-negative patients with symptomatic disease. Mechanism of Action: How Bdpoma 4 mg Works The efficacy of Bdpoma lies in its multi-faceted approach to destroying cancer cells: Cereblon Binding: Pomalidomide binds to the Cereblon (CRBN) protein, part of the E3 ubiquitin ligase complex. This leads to the targeted degradation of transcription factors (Ikaros and Aiolos), which are essential for the survival of myeloma cells. Immune System Augmentation: It enhances the activity of T-cells and Natural Killer (NK) cells, boosting the body’s innate ability to identify and eliminate tumor cells. Inhibition of Angiogenesis: It blocks the formation of new blood vessels (angiogenesis) that tumors require for oxygen and nutrient supply. Cytokine Regulation: It inhibits the production of pro-inflammatory cytokines like TNF-$alpha$ and IL-6, which contribute to tumor growth in the bone marrow microenvironment. Dosage and Administration Guidelines Standard Dosing: The typical dose is 4 mg orally once daily on Days 1–21 of repeated 28-day cycles. Method of Intake: Capsules must be swallowed whole with water. They should not be crushed, chewed, or opened. Consistency: Can be taken with or without food but should be taken at a consistent time each day to maintain steady plasma concentrations. Treatment Duration: Therapy is generally continued until disease progression or unacceptable toxicity occurs. Safety Profile and Clinical Monitoring Due to its high potency, Bdpoma 4 mg requires strict medical supervision: Hematological Vigilance: Common side effects include neutropenia (low white blood cell count), anemia, and thrombocytopenia. Regular Complete Blood Counts (CBC) are mandatory. Thromboembolism Prophylaxis: There is an increased risk of blood clots (DVT/PE). Patients are often prescribed prophylactic anticoagulants (like aspirin or heparin) alongside Bdpoma. Embryo-Fetal Toxicity (REMS): Pomalidomide is a known teratogen. Strict adherence to pregnancy prevention programs is mandatory for all patients of reproductive potential. General Side Effects: Patients may experience fatigue, constipation, diarrhea, or shortness of breath, which are managed through supportive care. Storage and Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Protection: Keep in the original blister packaging to protect from light and moisture. Safety: Caregivers should handle the capsules with care and avoid direct skin contact with the powder inside Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Pomalong 4 mg Capsule (Pomalidomide): Advanced Immunotherapy for Relapsed Multiple Myeloma Pomalong 4mg Capsule is a high-potency immunomodulatory drug (IMiD) containing the active pharmaceutical ingredient Pomalidomide. It is a third-generation thalidomide analogue specifically engineered to treat patients with complex hematological malignancies who have exhausted other treatment lines. Pomalong 4mg represents a critical advancement in oncology, providing a powerful option for managing refractory diseases by leveraging the body's own immune system to target and eliminate cancer cells. Therapeutic Indications and Clinical Usage Pomalong 4mg is a primary choice in international oncology protocols for: Relapsed and Refractory Multiple Myeloma (RRMM): Indicated for adult patients who have received at least two prior therapies, including both Lenalidomide and a proteasome inhibitor (such as Bortezomib), and have demonstrated disease progression. Combination Therapy: For maximum clinical efficacy, Pomalong is typically administered in combination with low-dose Dexamethasone. Kaposi Sarcoma (KS): Used for adult patients with AIDS-related Kaposi Sarcoma after failure of highly active antiretroviral therapy (HAART), or in HIV-negative patients with symptomatic disease. The Mechanism: How Pomalong 4 mg Works The active molecule, Pomalidomide, exerts its anti-cancer effects through a multi-faceted biological approach: Direct Tumor Inhibition: It binds to the protein Cereblon, part of an E3 ubiquitin ligase complex. This leads to the degradation of essential transcription factors (Aiolos and Ikaros), triggering apoptosis (programmed cell death) in myeloma cells. Immune System Modulation: It enhances the activity of T-cells and Natural Killer (NK) cells, empowering the body's natural defenses to identify and destroy malignant cells more aggressively. Anti-Angiogenesis: It blocks the development of new blood vessels that tumors rely on for oxygen and nutrients, effectively “starving“ the cancer. Cytokine Regulation: It inhibits the production of pro-inflammatory cytokines like TNF-$alpha$ and IL-6, which are known to fuel the growth of myeloma cells in the bone marrow microenvironment. Dosage and Administration Guidelines Standard Regimen: The recommended starting dose is 4 mg orally once daily on Days 1–21 of repeated 28-day cycles. Cycle Management: Patients usually take the 4 mg capsule for three weeks, followed by a 7-day rest period. Method of Intake: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Consistency: Can be taken with or without food, but should be taken at the same time each day to maintain steady therapeutic levels. Monitoring: Treatment continues until disease progression or until a physician determines that the side effects outweigh the clinical benefits. Safety Profile and Side Effect Management Clinical management of Pomalong 4 mg requires strict professional oversight: 1. Hematological Vigilance The most common side effects include neutropenia (low white blood cells), anemia, and thrombocytopenia (low platelets). Regular Complete Blood Counts (CBC) are mandatory to monitor for infection or bleeding risks. 2. Thromboembolism Prophylaxis There is a significantly increased risk of blood clots (DVT/PE). Patients are almost always prescribed prophylactic anticoagulants (like aspirin or heparin) concurrently with Pomalong. 3. Embryo-Fetal Toxicity (REMS) Pomalidomide is a known teratogen. Strict adherence to pregnancy prevention programs is mandatory for all patients of reproductive potential. 4. General Side Effects Commonly reported symptoms include fatigue, constipation, diarrhea, and shortness of breath. Proactive management with supportive care is essential for maintaining treatment adherence. Storage and Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Security: Keep capsules in the original blister pack to protect from light and moisture. Safety: Caregivers should avoid direct skin contact with the powder inside the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Pomide 4mg Capsule (Pomalidomide): Advanced Immunomodulatory Therapy for Multiple Myeloma Pomide 4mg Capsule is a high-potency anti-cancer medication featuring the active pharmaceutical ingredient Pomalidomide. It is a third-generation immunomodulatory imide drug (IMiD) specifically engineered to treat patients with relapsed or refractory Multiple Myeloma. Manufactured by Cipla Ltd., a global leader in pharmaceuticals, Pomide 4mg offers a vital therapeutic option for patients who have already undergone multiple lines of treatment, providing a targeted approach to inhibiting tumor growth and boosting the body's natural defenses. Therapeutic Indications and Clinical Usage Pomide 4mg is extensively utilized across international oncology protocols for: Relapsed and Refractory Multiple Myeloma (RRMM): Indicated for adult patients who have received at least two prior therapies, including both Lenalidomide and a proteasome inhibitor (such as Bortezomib), and have demonstrated disease progression. Combination Therapy: For maximum clinical efficacy, Pomide is typically administered in combination with low-dose Dexamethasone. Kaposi Sarcoma (KS): In certain regulatory environments, it is also used for adult patients with AIDS-related Kaposi Sarcoma after failure of highly active antiretroviral therapy (HAART). The Mechanism: How Pomide 4mg Works The active molecule, Pomalidomide, exerts its anti-cancer effects through a sophisticated multi-pathway mechanism: Tumor Cell Inhibition: It directly binds to the protein Cereblon, part of an E3 ubiquitin ligase complex. This leads to the degradation of essential transcription factors, triggering apoptosis (programmed cell death) in malignant cells. Immune System Modulation: It enhances the activity of T-cells and Natural Killer (NK) cells, significantly increasing the body's innate ability to identify and destroy cancerous cells. Anti-Angiogenesis: It blocks the formation of new blood vessels that tumors rely on for nourishment and growth, effectively “starving“ the malignant cells. Cytokine Regulation: It inhibits the production of pro-inflammatory cytokines like TNF-$alpha$ and IL-6, which are known to fuel the proliferation of myeloma cells in the bone marrow. Dosage and Administration Guidelines Cycle-Based Dosing: The standard dose is 4 mg orally once daily on Days 1–21 of repeated 28-day cycles. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Timing: It can be taken with or without food but should be taken at the same time each day to maintain steady therapeutic levels. Renal/Hepatic Adjustment: Dosage adjustments may be necessary for patients with impaired renal or hepatic function, as determined by a specialist. Safety Profile and Side Effect Management Clinical management of Pomide 4 mg requires vigilant professional oversight: Hematological Monitoring: The most frequent side effects include neutropenia (low white blood cell count), anemia, and thrombocytopenia. Regular Complete Blood Counts (CBC) are mandatory. Venous Thromboembolism (VTE): There is a significantly increased risk of blood clots. Patients are often prescribed prophylactic anticoagulants (like aspirin or heparin) concurrently. Embryo-Fetal Toxicity (REMS): Pomalidomide is a known teratogen. Strict adherence to pregnancy prevention programs is mandatory for all patients of reproductive potential. General Effects: Patients may experience fatigue, constipation, diarrhea, or shortness of breath, which are usually managed with supportive care. Storage and Handling Temperature: Store at room temperature, 20°C to 25°C. Security: Keep in the original blister pack to protect from light and moisture. Safety: Caregivers should avoid direct skin contact with the capsules to prevent accidental exposure to the active powder. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Pomide 4mg Capsule (Pomalidomide): Advanced Immunomodulatory Therapy for Multiple Myeloma Pomide 4mg Capsule is a high-potency anti-cancer medication containing the active ingredient Pomalidomide. It is a third-generation immunomodulatory imide drug (IMiD) specifically engineered to treat patients with relapsed or refractory multiple myeloma. Manufactured by Cipla Ltd., a global leader in pharmaceuticals, Pomide 4mg offers a vital therapeutic option for patients who have already undergone multiple lines of treatment, providing a targeted approach to inhibiting tumor growth and boosting the body's natural defenses. Therapeutic Indications and Clinical Usage Pomide 4 mg is extensively utilized across international oncology protocols for: Relapsed and Refractory Multiple Myeloma (RRMM): Indicated for adult patients who have received at least two prior therapies, including both Lenalidomide and a proteasome inhibitor (such as Bortezomib), and have demonstrated disease progression on or within 60 days of completion of the last therapy. Combination Therapy: For maximum clinical efficacy, Pomide is typically administered in combination with low-dose Dexamethasone. Kaposi Sarcoma (KS): In certain regulatory environments, it is also used for adult patients with AIDS-related Kaposi Sarcoma after failure of highly active antiretroviral therapy (HAART). The Mechanism: How Pomide 4mg WorksThe active molecule, Pomalidomide, exerts its anti-cancer effects through a sophisticated multi-pathway mechanism:Tumor Cell Inhibition: It directly binds to the protein Cereblon, part of an E3 ubiquitin ligase complex. This leads to the degradation of essential transcription factors, triggering apoptosis (programmed cell death) in malignant cells. Immune System Modulation: It enhances the activity of T-cells and Natural Killer (NK) cells, significantly increasing the body's innate ability to identify and destroy cancerous cells. Anti-Angiogenesis: It blocks the formation of new blood vessels that tumors rely on for nourishment and growth, effectively starving the malignant cells. Cytokine Regulation: It inhibits the production of pro-inflammatory cytokines like TNF-$alpha$ and IL-6, which are known to fuel the proliferation of myeloma cells in the bone marrow. Dosage and Administration Guidelines Cycle-Based Dosing: The standard dose is 4 mg orally once daily on Days 1–21 of repeated 28-day cycles. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Timing: It can be taken with or without food but should be taken at the same time each day to maintain steady therapeutic levels. Renal/Hepatic Adjustment: Dosage adjustments may be necessary for patients with impaired renal or hepatic function, as determined by a specialist. Safety Profile and Side Effect Management Clinical management of Pomide 4 mg requires vigilant professional oversight: Hematological Monitoring: The most frequent side effects include neutropenia (low white blood cell count), anemia, and thrombocytopenia. Regular Complete Blood Counts (CBC) are mandatory. Venous Thromboembolism (VTE): There is a significantly increased risk of blood clots. Patients are often prescribed prophylactic anticoagulants (like aspirin or heparin) concurrently. Embryo-Fetal Toxicity (REMS): Pomalidomide is a known teratogen. Strict adherence to pregnancy prevention programs is mandatory for all patients of reproductive potential. General Effects: Patients may experience fatigue, constipation, diarrhea, or shortness of breath, which are usually managed with supportive care. Storage and Handling Temperature: Store at room temperature, 20°C to 25°C (68°F to 77°F). Security: Keep in the original blister pack to protect from light and moisture. Safety: Caregivers should avoid direct skin contact with the capsules to prevent accidental exposure to the active powder. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383